| Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: a study of 200 cases J Lasota, A Wozniak, M Sarlomo-Rikala, J Rys, R Kordek, A Nassar, ... The American journal of pathology 157 (4), 1091-1095, 2000 | 418 | 2000 |
| MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema J Manner, B Radlwimmer, P Hohenberger, K Mössinger, S Küffer, ... The American journal of pathology 176 (1), 34-39, 2010 | 304 | 2010 |
| Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients O Maertens, H Prenen, M Debiec-Rychter, A Wozniak, R Sciot, P Pauwels, ... Human molecular genetics 15 (6), 1015-1023, 2006 | 282 | 2006 |
| Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases J Lasota, CL Corless, MC Heinrich, M Debiec-Rychter, R Sciot, ... Modern pathology 21 (4), 476-484, 2008 | 247 | 2008 |
| A precision therapy against cancers driven by KIT/PDGFRA mutations EK Evans, AK Gardino, JL Kim, BL Hodous, A Shutes, A Davis, XJ Zhu, ... Science translational medicine 9 (414), eaao1690, 2017 | 226 | 2017 |
| Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour–the impact of tumour rupture on patient outcomes P Rutkowski, E Bylina, A Wozniak, ZI Nowecki, C Osuch, M Matlok, ... European Journal of Surgical Oncology (EJSO) 37 (10), 890-896, 2011 | 206 | 2011 |
| Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a European multicenter analysis based on ConticaGIST A Wozniak, P Rutkowski, P Schöffski, I Ray-Coquard, I Hostein, ... Clinical cancer research 20 (23), 6105-6116, 2014 | 188 | 2014 |
| Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for … P Schöffski, J Sufliarsky, H Gelderblom, JY Blay, SJ Strauss, S Stacchiotti, ... The Lancet Respiratory Medicine 6 (6), 431-441, 2018 | 178 | 2018 |
| Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience A Wozniak, P Rutkowski, A Piskorz, M Ciwoniuk, C Osuch, E Bylina, ... Annals of oncology 23 (2), 353-360, 2012 | 178 | 2012 |
| Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas P Lagarde, J Przybyl, C Brulard, G Pérot, G Pierron, O Delattre, R Sciot, ... Journal of clinical oncology 31 (5), 608-615, 2013 | 166 | 2013 |
| Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor–associated PDGFRAD842V mutation B Dewaele, B Wasag, J Cools, R Sciot, H Prenen, P Vandenberghe, ... Clinical Cancer Research 14 (18), 5749-5758, 2008 | 156 | 2008 |
| Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal TumorsGIST Prognosis Based on Mitosis-Related Gene Expression P Lagarde, G Pérot, A Kauffmann, C Brulard, V Dapremont, I Hostein, ... Clinical cancer research 18 (3), 826-838, 2012 | 154 | 2012 |
| Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial P Schöffski, A Wozniak, B Escudier, P Rutkowski, A Anthoney, S Bauer, ... European Journal of Cancer 87, 147-163, 2017 | 136 | 2017 |
| Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status A Wozniak, R Sciot, L Guillou, P Pauwels, B Wasag, M Stul, ... Genes, Chromosomes and Cancer 46 (3), 261-276, 2007 | 127 | 2007 |
| Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease P Schöffski, J Cornillie, A Wozniak, H Li, D Hompes Oncology research and treatment 37 (6), 355-362, 2014 | 126 | 2014 |
| Identification of a novel, recurrent MBTD1‐CXorf67 fusion in low‐grade endometrial stromal sarcoma B Dewaele, J Przybyl, A Quattrone, J Finalet Ferreiro, V Vanspauwen, ... International journal of cancer 134 (5), 1112-1122, 2014 | 124 | 2014 |
| Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors J Lasota, B Wasag, A Wozniak, E Kraszewska, W Michej, K Ptaszynski, ... Laboratory investigation 87 (10), 1029-1041, 2007 | 105 | 2007 |
| Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial … P Schöffski, A Wozniak, S Stacchiotti, P Rutkowski, JY Blay, LH Lindner, ... Annals of Oncology 28 (12), 3000-3008, 2017 | 103 | 2017 |
| The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis S Boichuk, JA Parry, KR Makielski, L Litovchick, JL Baron, JP Zewe, ... Cancer research 73 (16), 5120-5129, 2013 | 102 | 2013 |
| MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours CMM Gits, PF van Kuijk, MBE Jonkers, AWM Boersma, WF Van Ijcken, ... British journal of cancer 109 (6), 1625-1635, 2013 | 100 | 2013 |
